Portfolio

Macrobiome

Developing macrobiota-inspired therapeutics for improved human health.
Up Arrow Icon

Macrobiome

→

Leaders
Alex Loukas
Alex Loukas
Co-Founder and Co-CSO
Dr Paul Giacomin
Dr Paul Giacomin
Co-Founder and Co-CSO
Dr Keats Nelms
Dr Keats Nelms
CEO
Investment Team
challenges
Autoimmune and inflammatory diseases like IBD and Type 2 Diabetes affect hundreds of millions globally, yet existing treatments are narrow in scope, carry debilitating side effects, and offer limited long-term efficacy. The unmet need for safer, more effective biologics remains enormous.
solution
Parasitic helminths have co-evolved with their human hosts for millions of years, developing proteins that quietly suppress immune overreaction without causing harm. Macrobiome has built a proprietary library of these helminth-derived proteins and is mining it to develop a new class of biologics for IBD, Type 2 Diabetes, and wound healing — treatments inspired by nature rather than synthesised from scratch.
For founders

Building for the systems that matter? Pitch us.

We back founders turning breakthrough science into category-defining companies.

Submit your pitch
For investors

Invest with Main Sequence

Access Australia's deep tech frontier alongside us.

Investor enquiries